AU2019285065A1 - Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration - Google Patents
Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration Download PDFInfo
- Publication number
- AU2019285065A1 AU2019285065A1 AU2019285065A AU2019285065A AU2019285065A1 AU 2019285065 A1 AU2019285065 A1 AU 2019285065A1 AU 2019285065 A AU2019285065 A AU 2019285065A AU 2019285065 A AU2019285065 A AU 2019285065A AU 2019285065 A1 AU2019285065 A1 AU 2019285065A1
- Authority
- AU
- Australia
- Prior art keywords
- aminosterol
- dose
- subject
- derivative
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684496P | 2018-06-13 | 2018-06-13 | |
US62/684,496 | 2018-06-13 | ||
PCT/US2019/036946 WO2019241503A1 (fr) | 2018-06-13 | 2019-06-13 | Méthodes et compositions pour traiter et/ou prévenir la progression et/ou l'apparition de la neurodégénérescence liée à l'âge |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019285065A1 true AU2019285065A1 (en) | 2021-01-07 |
Family
ID=68838925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019285065A Pending AU2019285065A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Country Status (11)
Country | Link |
---|---|
US (2) | US20210252023A1 (fr) |
EP (1) | EP3806862A4 (fr) |
JP (1) | JP2021527090A (fr) |
KR (1) | KR20210009422A (fr) |
CN (1) | CN112566641A (fr) |
AU (1) | AU2019285065A1 (fr) |
BR (1) | BR112020025296A2 (fr) |
CA (1) | CA3103463A1 (fr) |
MX (1) | MX2020013614A (fr) |
SG (1) | SG11202012343TA (fr) |
WO (1) | WO2019241503A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020028810A1 (fr) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau |
EP3829537A4 (fr) * | 2018-08-03 | 2022-09-21 | Enterin, Inc. | Formes posologiques d'aminostérol intranasale à faible dosage et procédés d'utilisation associés |
US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
CN110827282B (zh) * | 2020-01-13 | 2020-04-10 | 南京慧脑云计算有限公司 | 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统 |
CN111110873A (zh) * | 2020-02-24 | 2020-05-08 | 苏州欣影生物医药技术有限公司 | 一种磁共振/核医学双模态分子影像探针的制备方法 |
CN111528839B (zh) * | 2020-05-29 | 2023-06-23 | 北京京东方健康科技有限公司 | 睡眠检测方法和装置、助眠设备和方法 |
CA3219821A1 (fr) * | 2021-05-21 | 2022-11-24 | Sang-Jin Lee | Composition comprenant un inotodiol pour la prevention ou le traitement d'une maladie musculaire |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
TW200927755A (en) * | 2007-09-06 | 2009-07-01 | Genaera Corp | A method for treating diabetes |
WO2011066260A2 (fr) * | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprenant des aminostérols |
US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2019
- 2019-06-13 AU AU2019285065A patent/AU2019285065A1/en active Pending
- 2019-06-13 SG SG11202012343TA patent/SG11202012343TA/en unknown
- 2019-06-13 KR KR1020217000559A patent/KR20210009422A/ko not_active Application Discontinuation
- 2019-06-13 CA CA3103463A patent/CA3103463A1/fr active Pending
- 2019-06-13 EP EP19818961.5A patent/EP3806862A4/fr active Pending
- 2019-06-13 BR BR112020025296-4A patent/BR112020025296A2/pt unknown
- 2019-06-13 WO PCT/US2019/036946 patent/WO2019241503A1/fr unknown
- 2019-06-13 CN CN201980052151.2A patent/CN112566641A/zh active Pending
- 2019-06-13 US US17/251,322 patent/US20210252023A1/en not_active Abandoned
- 2019-06-13 US US16/440,414 patent/US20190381071A1/en not_active Abandoned
- 2019-06-13 MX MX2020013614A patent/MX2020013614A/es unknown
- 2019-06-13 JP JP2020569002A patent/JP2021527090A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210009422A (ko) | 2021-01-26 |
EP3806862A4 (fr) | 2022-07-06 |
MX2020013614A (es) | 2021-05-27 |
CA3103463A1 (fr) | 2019-12-19 |
EP3806862A1 (fr) | 2021-04-21 |
WO2019241503A1 (fr) | 2019-12-19 |
SG11202012343TA (en) | 2021-01-28 |
US20190381071A1 (en) | 2019-12-19 |
CN112566641A (zh) | 2021-03-26 |
BR112020025296A2 (pt) | 2021-03-09 |
JP2021527090A (ja) | 2021-10-11 |
US20210252023A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210252023A1 (en) | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration | |
JP7312169B2 (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
JP6957602B2 (ja) | 神経変性疾患のための治療薬 | |
KR102467953B1 (ko) | 리소좀 축적 질환과 관련된 약제 조성물 및 용도 | |
US20230123701A1 (en) | Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same | |
JP2012500801A (ja) | Cns疾患の治療法 | |
EP3829587A1 (fr) | Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau | |
US20190298740A1 (en) | Methods and compositions for treating hallucinations and conditions related to the same | |
JP2016538269A (ja) | 筋ジストロフィーの処置のための方法 | |
US20200129528A1 (en) | Methods for treating blood pressure conditions using aminosterol compositions | |
KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
JPWO2019241503A5 (fr) | ||
US20210260078A1 (en) | Low dosage intranasal aminosterol dosage forms and methods of using the same | |
US20200038413A1 (en) | Methods of treating parkinson's disease using aminosterol compositions | |
CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 | |
US20210315907A1 (en) | Compositions and methods for treating brain-gut disorders | |
US20200038417A1 (en) | Methods and compositions for treating cognitive impairment | |
US20200038419A1 (en) | Methods of treating multiple system atrophy using aminosterol compositions | |
Malaspina et al. | Disorders of the Motor Cells: The Motor Neuron Diseases | |
WO2023146838A1 (fr) | Méthodes de traitement ou de prévention d'une maladie neurodégénérative à l'aide d'une association d'aminostérols et d'un composé d'insuline | |
US20200038418A1 (en) | Methods of treating autism spectrum disorder using aminosterol compositions | |
Abe et al. | WFN15-1473 Movement Disorders Effects of zonisamide for overall non-motor symptoms with Parkinson’s disease patients | |
WO2014088106A1 (fr) | Agent prophylactique ou thérapeutique pour la fibromyalgie | |
Chu | Weakness and Stiffness of Both Hands |